Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)
Completed
OraPharma
Phase 3
2012-05-01
The objective of the study is to evaluate the safety, effectiveness and anti-microbial
effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with
peri-implantitis, when used in combination with mechanical debridement.
The hypothesis of the study is that Arestin in combination with mechanical debridement is
more effective in the treatment of peri-implantitis when compared to mechanical debridement
alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as
measured at qualifying implant sites.
There is mounting evidence to suggest that a treatment for Angelman syndrome is not just
possible, but probable. The lack of known molecular targets associated with AS has hampered
the development of specific therapeutics. However, a recent surge of potential therapeutics
for other disorders associated with cognitive disruption has begun to be used in human
clinical trials. The molecular modes of action for many of these new therapeutic agents have
correlates to counter the molecular defects observed in AS. One such agent is minocycline
(MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model
of AS showed a significant decrease in motor deficit and an increase in long term
potentiation. The investigators believe a similar result will be observed when minocycline is
administered to the AS patient and may lead to the development of an effective AS
therapeutic.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
